

Human CD19 Monoclonal Antibody (N297Q)

Catalog No.: YR0502

Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/μg) Determined by
LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Loncastuximab Biosimilar

Isotype

Human IgG1 kappa


Immunogen

Recommended Isotype Control(s)


Recommended Dilution Buffer

1×PBS pH 7.3

Contact

 | 400-999-6126

 | cn.market@abclonal.com.cn

 | www.abclonal.com.cn

Product Information

Production

Purified from cell culture supernatant in an animal-free facility


Purification

Protein A or G purification


Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Validation Data



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD19 (Research Grade Loncastuximab(N297Q) Biosimilar) Monoclonal Antibody to CD19. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.



Human CD19 SPR assay. Determined through SPR assay, the Human Anti-Human CD19 (Research Grade Loncastuximab (N297Q) Biosimilar) Monoclonal Antibody is Capable of binding to Human CD19 with an affinity constant of 1.288nM.